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1 Introduction and aim of the work 
 
 
In this dissertation, different kinds of macromolecular structures have been considered as 
the carrier for the delivery of artemisone (ART) as an effective antimalarial substance. In 
different clinical studies, ART could demonstrate its effectiveness against P. falciparum 
successfully. One of the challenges in the practical use of artemisinins (ACTs) as 
hydrophobic drugs, is the dosage that should be optimal for efficacy and lack of toxicity.  
In all research works that have been reported in this thesis, different types of carriers 
could be applied to produce the programmed/controlled drug release systems, which 
could be a solution for maintaining the optimal dosage of ART for more extended periods. 
The time-dependent release of a drug with or without external stimuli is referred to as a 
controlled release in general literature. 
In an ideal case, a delivery system should provide immediate initial therapeutic drug 
concentration (burst dose) and then maintain this concentration for an extended period 
(sustained dose) depending upon the requirement. Further, the rate of sustained release 
of therapeutic concentration should match the rate of the absorption by the body in order 
not to exceed the toxic level. This gets more complicated as physiological conditions, and 
therefore the rate of drug absorption varies from person to person. An ideal controlled 
release system for diseases like malaria should provide imminent release of one or more 
drugs, according to personal requirements. This should be independent of the 
environmental influence, in a reproducible manner, accessible and usable even under 
rural conditions, not requiring complicated technology, and also programmable according 
to the type and status of the infection. 
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In this thesis, different classifications of materials based on electrospun nanofibers, 
polymeric films, 3D structures, and particles could be successfully applied to carry the 
ART. Drug molecules could be efficiently immobilized in these materials, and the drug 
release from these carriers could be adequately studied. Effectively, the kinetics of the 
ART release from macromolecular carriers could be adjusted by modification of the 
carrier.   
The primary target of this Ph.D. work was the establishment of not only a scientific study 
for delivery of an antimalarial but also a fundamental study to focus on the polymeric 
structures as the drug carrier with focusing on the advantage and disadvantage of each 
system for delivery of mainly hydrophobic drugs with low water solubility. Today, 
nanotechnology is considered as an exciting opportunity for the delivery of hydrophobic 
drugs which have low bioavailability. 
Furthermore, the real application of such polymeric carrier in the real world was one of 
the main concerns. Therefore, besides the real in vivo experiments (implantation of ART 
loaded scaffolds in mice), we tried to introduce another administration route based on the 
setting up of a delivery system based on the infusion system. We suggest that the 
combination of the advantage of precise and reproducible programmed release from 
nanofiber nonwovens (NFN) in vitro with the drug delivery infusion system is very 
beneficial. In our system, the control over drug release is achieved outside the 
physiological environment by placing ART-loaded NFN in the drip chamber of an infusion 
system, which can flexibly release ART.  
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2 Theoretical background and overview of the literature 
 
2.1 Drug delivery carriers and systems (DDS) 
DDS are designed to consistently introduce therapeutic agents into the body at a required 
dose level and rate [1-5]. Maybe, one of the first attempts to set up the DDS was reported 
in the 1960s when Folkman circulated rabbit blood inside a silicone rubber and found out 
that if he opened the tubing to anesthetic gases on the outside, the rabbits would fall 
asleep. It was then offered that such short, sealed segments of such a system containing 
a drug could be placed and could become a constant rate drug delivery device [6]. Drug 
delivery systems can be fabricated to adjust the pharmaceutical parameters like the 
pharmacokinetics and the distribution of related medicines to the utility as the drug 
carriers [7]. The pharmacological characteristics of conventional medicines can be 
improved through the application of DDS. Drug delivery systems are supporting us in 
gaining the novel therapeutically curative ways for the successful treatment of diseases 
due to their benefits. The main advantages of DDS involve increasing drug solubility, 
reduction in toxicity, protection of the drug from rapid decomposition and degradation, 
and finally, reduction in side effects in patients, especially in non-target tissues. The 
controlled release systems or controlled drug delivery systems for different types of 
medicines have been widely fabricated due to their advantages. Among different 








Figure 2 Different types of polymeric carriers used as delivery vehicles for targeted drug delivery 
 
Various benefits of DDS compared to other methods of drug administration routes have 
been reported [8-9]. These advantages involve a reduction in the side effects of systemic 
administration by local administration from a controlled release system, improved drug 
administration in areas where proper medical supervision is not available, continuous 
release of small quantities of drug instead of harmful or toxic large doses, and 
improvement of patient compliance [10-11]. In order to reach these goals, several 
parameters should be considered in a controlled drug delivery system or a drug carrier; 
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such as the nature of delivery carrier materials, the drug properties, route of 
administration, mechanism of drug release, the ability of targeting, and biocompatibility 
(Fig. 3). 
 
Figure 3 Stimuli-responsive targeted delivery of therapeutic agents; Schematic illustration of stimuli-
responsive DDS [7] [Permission: this is an open article distributed under the terms of the creative commons 
CC BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
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In the past years, a variety of biocompatible DDS has been prepared with improved 
properties. It was demonstrated that when a pharmaceutical agent or molecule is 
encapsulated within, or attached to a carrier, drug efficacy and safety may be improved. 
The concept facilitates active researches for the design of biocompatible and 
biodegradable materials as drug delivery systems. Recent research works have led to the 
development and improvement of a new approach in the field of controlled drug delivery 
or controlled drug release system with the creation of nano-sized biodegradable 
polymeric drug delivery systems [12-14]. The critical requirement of a controlled drug 
release system is to allow sustained release of the active agent continuously over an 
extended period of time to obtain a consistent therapeutic drug release profile which 
duration of delivery, route of administration, drug properties, mechanism of drug release, 
biocompatibility, the nature of the delivery ability to the targeting results in extended 
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2.1.1 Controlled DDS by electrospun structures 
Nanofibers have attracted much attention for various medical applications [17-20]. The 
advantages of nanofibers are derived from their high specific surface area and the 
formation of the highly porous surface [21-23]. Medical applications of nanofibers are 
included to fabricate wound dressings [24-25] tissue engineering scaffolds [26-27] and 
nanofibrous drug (pharmaceutical agent) delivery systems [28-30]. There are different 
techniques to fabricate nanofibers, including phase separation, melt-blown, self-
assembly, phase template, and electrospinning [31-32]. 
Electrospinning is a state-of-the-art method of making porous nanofibrous structures, and 
it has received much and much attention because it is a versatile, adaptable and 
straightforward technique to fabricate nanofibrous membranes from a broad wide range 
of polymers in a relatively easy and straightforward way [33-35]. The setup for 
electrospinning consists of three major components: 1. a high-voltage power supply, 2. a 
spinneret (a metallic needle), and 3. a collector (Fig. 4). The spinning mechanism is partly 
complicated due to complex electro-fluid mechanical forces involved. In the process of 
electrospinning, the polymer solution housed in a syringe is fed through the spinneret at 
a constant and controllable rate. The electrostatic field exists in the space of the 
electrospinning device when a high voltage is applied. The electrostatic field charges the 
solution drop at the nozzle of a spinneret and the induced charges are evenly distributed 
over the surface. Under the action of electrostatic interactions, the drop is distorted into a 
sharp object that is called a “Taylor cone.” The electrified jet can be attracted by the 
collectors, and it is directed towards the collector with the opposite electrical charge.  
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As it travels to the collector, the solvent is evaporated, and the solid polymer nanofiber is 





   
 
Figure 4 a) A schematic structure of an electrospinning process. b) Microscopic structures of nanofibers 
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2.1.2 Controlled DDS by polymeric films 
 
Drug delivery by polymeric films using a film, something like a tablet to administer drugs 
via absorption in the mouth (buccally or sublingually), via the small intestines (enterically) 
or for subcutaneous applications like implantation offers many advantages for controlled 
DDS system [36-37]. The process of fabrication of such carriers is technically very 
straightforward and procurable. Pharmaceutical scientists around the world are trying to 
explore the polymeric films as the novel DDS tool. Films have played an essential role as 
an alternative approach to conventional dosage forms. Such films have been considered 
to be convenient to swallow, self-administrable, and fast dissolving dosage form, all of 
which make it a versatile platform for drug delivery. This drug delivery system has been 
used for both systemic and local action via several routes such as oral, buccal, sublingual, 
ocular, and transdermal routes. The design of these effective drug-loaded films needs a 
comprehensive knowledge of the pharmacological and pharmaceutical properties of 
drugs and polymers, along with an appropriate selection of manufacturing processes. 
A film can be prepared either by applying hydrophilic polymers that rapidly dissolve on 
the tongue, transferring the drug to the systemic circulation via dissolution when contact 
with the liquid is present or by application of hydrophobic polymeric carriers which support 
the retarded drug release [38-39]. Currently, a significant amount of original works in 
literature, but there is still a need for extensive studies to optimize the performance of 
drug-loaded films accurately. The lack of appropriate guidance for the manufacture, 
characterization, and quality control of such drug-loaded films has absorbed the need of 
adequate studies in this area from the pharmaceutical aspects. 
. 





Figure 5 A fabricated film based on heat-press technique containing 2 mg antimalaria drug, artemisone. 
 
2.1.3 Controlled DDS by 3D structures 
 
Drug delivery systems achieved from 3-dimensional (3D) structures is a rapidly growing 
area of research studies. It is essential to achieve structures in what drug stability is 
ensured; the drug loading capacity is suitable, and the desired controlled release profile 
can be gained. It should be considered that the development of appropriate fabrication 
that allows 3D drug delivery systems (DDS) to be fabricated in a simple, reliable, and 
reproducible manner. The range of production methods at the moment being used to form 
3D DDS involving electrospinning (in the form of solution or melt), wet-spinning, and 3D-
printing. The application of these techniques enables the production of DDS from the 
macro-scale down even to the nanoscale [40,41]. There is an increasing interest in the 
fabrication of three dimensional (3D) macro-, micro- or nanoscale systems prepared from 
polymeric (macromolecular) structures that may find potential applications in tissue 
engineering scaffolds and drug delivery systems. Drug delivery by 3D structures is 
gaining growing attention in pharmaceutical formulation development as a practical path 
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to overcome many challenges of conventional pharmaceutical formulations. For instance, 
the standard manufacturing involving milling, mixing, granulation, and compression can 
result in different qualities of the final products regarding drug loading, the kinetics of the 
drug release, the stability of the drug, and the stability of the pharmaceutical dosage form.  
DDS fabricated from 3D structures have enabled flexibility in the design and production 
of complex carriers, which can be used in controlled and programmable pharmaceutics. 
Among 3D structures, porous materials have attracted a great deal of attention due to 
their low density, high surface area, and large porosity and have been widely applied for 
drug delivery purposes. The ordered open pore structure, the high surface area, and the 
high porosity are essential for optimum loading and controlled release. The large surface 
area leads to the high drug adsorption, which can be stored and released from meso and 
micropores on the surface or in bulk. A novel class of polymeric three-dimensional (3D) 
sponges made from short electrospun fibers have attracted growing interest. The capacity 
of these sponges for the uptake of liquids was found to be as high as 100× the mass of 
the sponge itself. Such sponges could be an ideal macroporous carrier for drugs, with 
high loading and intrinsic mechanical compressibility and multiple potential uses. This 
would allow the implantation of the drug-loaded sponge. 
 
 




Figure 6 Schematic imagination of a 3D structure (ultralight and ultra-porous material loaded by antimalarial 
artemisone [42]; [Permission has been granted.] 
 
2.1.4 Controlled DDS by particulate systems 
 
Many solid dosage formulations in the pharmaceutical industries are based generally on 
particles, especially microparticles. Dried powders are inhaled into the lung, transferred 
to the nose, filled into capsules, or pressed in the form of tablets for oral applications, or 
even delivered transdermally. In the past, microparticles were often considered merely as 
carriers, usually micronized dry material, without sophisticated attributes [43-44]. The 
primary purposes of the micronization and drying processes were to obtain suitable 
particle size and remove the main content of the solvent. This point of view has changed 
as novel drug delivery strategies were developed and improved. The advanced 
therapeutic approaches have established complex requirements for dosage forms, which 
can only be obtained by particles that are purposed for a range of functions such as 
stabilization of the active agent, transport and targeting of the dose, or release 
management. The particle is no longer observed as a passive carrier, but rather as an 
essential part of the drug delivery system [45-46]. 
 
Controlled Release of Antimalarial Artemisone by Macromolecular Structures 
19 
 
Attempts to realize and control particle formation processes were increased in the last 
years, corresponding with the development of pulmonary therapeutics that were 
commonly given by injection. The pulmonary route was found mainly to be viable for the 
systemic delivery of proteins and peptides, for example insulin, triggering the 
development of diverse administration systems and particle engineering strategies. 
Microparticles can be fabricated by many different processing methods. Wet chemistry 
and phase separation treatments and alternative drying processes such as spray freeze 
drying, or supercritical fluid technologies, have also been applied widely for particle 
fabrication purposes. 
Spray-drying is a rapid, continuous, cost-effective, and reproducible process for the 
fabrication of dry powders from a fluid material by atomization through an atomizer into a 
hot drying gas medium (usually air). Often spray-drying is considered only as a 
dehydration process. However, it can be applied for the encapsulation of hydrophilic or 
hydrophobic active compounds within different carriers without substantial thermal 
degradation as well, even of heat-sensitive (active) substances due to fast drying (in 
seconds or milliseconds) and relatively short exposure time to heat. The gained solid 
particles present relatively narrow size distribution at the submicron-to-micron scale 
[47,48]. 
 




Figure 7 Mechanism of a spray-drying process [49]; [Permission: this is an open article distributed under 
the terms of the creative commons CC BY license, which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited.] 
2.2 Controlled drug release from polymeric carries 
 
Controlled drug delivery technology introduces one of the most rapidly advancing areas 
of science and technology in which chemists and pharmacists are contributing to human 
health care. Such delivery systems offer various benefits comparing to conventional 
dosage forms, including improved efficacy, decreased toxicity, and increased patient 
compliance and comfort. Such systems often employ synthetic polymers as carriers for 
the drugs. All controlled drug delivery and release systems aim to improve the 
effectiveness of drug therapy. This refinement can take the form of improving therapeutic 
activity comparing to the intensity of side effects, minimization of the number of drug 
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administrations required during treatment, or eliminating the need for specialized drug 
administration (e.g., repeated several injections) [50-52].  
The drug-release mechanism can be physical or chemical in nature. Diffusion is always 
revolved for non-biodegradable matrix and membrane devices; the release is by diffusion 
and is driven by the concentration gradient. It can also be driven by osmotic pressure or 
matrix swelling. For matrices that are biodegradable or contain drug conjugates, the 
release is controlled by the hydrolytic or enzymatic cleavage of the relevant chemical 
bonds, although diffusion of the reactants and the free drug molecules may still be rate-
limiting. Only a qualitative discussion is pursued here for understanding the release 
patterns ensuing from the more common delivery systems [53-56]. 
 
Figure 8 Design of polymeric carrier regarding the necessary background-requirements 
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2.2.1 Mechanism of controlled drug release from polymeric carries 
Drug release systems can be classified into two main classes: 1. sustained release and 
2. controlled release. Sustained-release systems are generally a mix of agents that 
affect the net rate of dissolution of the drug molecule. Controlled-release systems are 
established from a drug molecule (i.e., active agent) and a biocompatible carrier such as 
a polymer. This system also involves an operation that can be free or connected to the 
polymer chain, which allows for handling the release kinetics of the system. Controlled 
drug delivery systems can be applied to a person through oral, ocular, parenteral, and 
sublingual sites. 
 
2.2.1.1 Diffusion-Controlled Systems 
The process of the drug release in an aqueous environment has several main benefits in 
terms of the planning of the control and response of the system. The rate at which water 
can swell the matrix of a polymeric system can be significantly rapid. The term “diffusion” 
is related to the actions of the drug molecules upon exposure to stimuli affecting its 
external environment. The rate-limiting step of diffusion drug release systems is the 
diffusion through typically a water-insoluble barrier. The diffusion DDS are typically either 
matrix-based or reservoir diffusion systems [57-58]. In the matrix-based systems, the 
drug is combined with a polymer to shape a composite matrix where water permeation 
makes for either swelling or osmotically controlled systems. Since the matrix is composed 
of both polymeric carrier and drug molecules, the swelling influence is observed as a 
steady volume expansion of the bulk polymeric material, causing the opening of pores 
throughout the matrix structure [59-60]. To happen an effective diffusion of drug 
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molecules, the pore size of the swelled matrix has to exceed the size of the hydrophilic 
drug molecule or hydrophobic medicine particle significantly. In reservoir systems, the 
drug solution or dispersion is encapsulated within or into a polymer, creating a leaky 
barrier between the drug solution environment and the surrounding environment. Since 
the reservoir is composed of a polymer barrier coating, the swelling effect is observed as 
non-uniform volume expansion, that the barrier coating allows for water permeability and 
swells, while the internal ingredients can diffuse out of the system. This is not unlike a 
















Controlled Release of Antimalarial Artemisone by Macromolecular Structures 
24 
 
2.2.1.2 Degradation-Controlled drug delivery Systems 
 
The main modes of erosion-based drug delivery systems are through the release of the 
drug molecule, characteristically from a bulk phase that includes a drug composite. Thus, 
the rate-limiting step of degradation-controlled release systems is dissolution [61-63]. 
 
Table 1 Common erosion effects encountered by biomedical materials 
      Erosion effects Remarks 
Adhesion  Physical interaction with another surface. 
Erosion Failure of material due to hard materials that are pressed 
against the surface. 
Cavitation Physical interaction with another physical state. 
Fatigue (exhaustion) Fatigue happens when a material is subjected to repeated 
loading and unloading. 
Corrosion The gradual destruction of materials by chemical and 
electrochemical reaction with their environment. 
 
The composite can involve a polymer of a tailored degradation or deformation rate. The 
degradation or dissolution effects are evaluated as the erosion of the material over time 
in response to its immediate physiological environment. The erosion can happen through 
a variety of mechanisms related to either the surface or the bulk of the material. Erosion 
on the surface generates displacement of surface features or regularity due to several 
common effects (Table 1). 
The degradation or deformation rate is evaluated from a matrix because of the adsorption 
or circulation of physiological, typically aqueous liquid around the body. In these matrices 
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or monoliths, systems, the drug is homogeneously dispersed throughout a matrix. The 
changes to the bulk state can be divided into two main categories: bulk erosion and 
surface erosion. 
In the case of the bulk erosion, the material degrades or deforms regularly throughout the 
bulk of the material. As the deformation continues, the volume of the material remains 
constant while the mass of the material decreases, resulting in a decrease in the density 
of the degrading material. In the case of surface erosion, the material degrades (or 
deforms) from the outer surface inside only at the interface between the bulk of the matrix 
and the external environment. As the deformation occurs, the volume of the material 




Figure 9 Degradation-Controlled Systems based on bulb and surface erosion 
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This is a critical differentiation between the two attempts that distinguish their responses 
to physical stress and dictates their application. Materials that keep volume but reduce 
density become porous and fragile over time, with weaker mechanical integrity. This effect 
can happen with swelling or dissolution, covalent bond break, and secondary bond 
dissociation within the system. Materials with fragile and porous structures are like weak 
ceramics that can crumble or crack in response to shear, compression, or tensile stress. 
If materials density is constant, they will have more calculable behavior to external 
physical stresses. If the volume is decreased, however, the function of the material may 
be compromised. 
 
2.3 Factors affecting the drug release 
The controlled release systems are primarily fabricated as matrix systems or reservoir 
types, which are more straightforward to design yet useful and programmable to release 
the drug at the desirable rate (kinetics). These systems create high and dynamic 
concentration flows across tissues and are hard to identify, characterize, and control [66-
67]. The release kinetics for DDS are influenced by all constituents of which the DDS are 
formulated and the parameters of the process under which it is covered. The principal 
parameters on which release is dependent are depicted in Figure 10 and can govern the 
drug release rate individually and mutually. Many other biological parameters should also 
be considered simultaneously while investigating drug release kinetics for a given system. 
The delivery of the drug via diffusion-convection, biological properties of tissue and 
arterial ultrastructure, hydrodynamic conditions at the implantation site, and stent design 
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significantly modulate the release rate and the final biological response to drug-eluting 
DDS [68-70].  
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Table 2 Factors affecting the rate of drug release in details  
Parameters 
 
Possible effects on 
Basic properties of the applied drug 
 
Drug hydrophobicity/hydrophilicity aqueous solubility and local drug concentrations 
Diffusion/dissolution characteristics  release kinetics   
Solubility/mixability in a polymeric matrix release kinetics   
Solubility in release media with higher degrees of solubility, higher drug release 
rates 
Properties of the rate-controlling polymer 
 
Thermal properties (Tm, Tg ) affects degradation, hydrophobicity, drug release and 
drug solubility in the case of biodegradable polymers 
Degree of crystallinity affects water penetration and drug solubility in the case 
of non-erodible polymers Influences degradation and 
drug release for biodegradable polymers 
For biodegradable polymers- initial 
molecular weight, copolymer ratio, 
absorption rate and period, the pH of 
dissolution medium 




Selection of coating process coating film property and drug elution  
Properties of solvent (BP, thermal 
history), Solvent evaporation rate and 
Phase diagram of the ternary system 
(drug-polymer-solvent)  
residual solvent effects, merging of coating layers, thus 
influencing release kinetics 
Drug to polymer ratio  effect on the drug-carrying capacity of polymer and 
drug elution rate   
Drug (initial solid phase) concentration 
and distribution inside the matrix  
Describes initial burst effect and dissolution 
mechanism  
Coating design  
 
Coating layer composition and thickness  affects the diffusion of drug through the carrier  
The microstructure of coating (spatial 
variation in physical and chemical 
composition)  
exhibits process conditions and eventual effect on drug 
delivery kinetics  
Mechanical properties of the coated drug-
loaded carrier 
the improper coating may induce adverse and 
interrelated effects such as local inflammation and 
thrombosis and hinder homogeneous drug uptake  
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2.4 Administration of drug-loaded polymeric carriers 
Although recent studies have developed and summarized several novel aspects for 
micro- and nanomaterials that are applied as smart drug carriers, few of them have been 
finally translated into clinics for real-world applications [71-73]. There are different 
essential components that should be considered to ensure the clinical potential for real 
future applications. On the one hand, the construction of nanomaterials as drug carriers 
should contain the following critical issues:  
1. satisfactory behaviors according to biocompatibility and biodegradability; 2. good 
stability in physiological environments; and 3. high capacity of drug loading and low 
toxicity nature.  
Additionally, apart from the primary requirement for safety and therapeutic efficacy, 
industrialization for DDS is also a requirement for this type of novel nanomaterials in 
clinical applications. For the design of the, in reality, applicable DDS should be 
concentrated on some of the important scientific backgrounds (Fig. 11).  
 
 




Figure 11 Essential compounds for the engineering of the DDS 
 
Considering such physical, chemical, and biologicals elements can help effectively to 
manage the useful DDS, and unpleasant end-results can be avoided (Fig. 11 and Table 
3). 
Table 3 Necessary prerequisites to be considered for applicable DDS 
Essential compounds for the design of polymeric DDS 
carrier blood Target organ excretion clinics 




Safe and easy 
application 
Drug stabilization Controlled drug 
release 
















No cytotoxicity Excretion by liver Easy to use and 
store 
biocompatible No cause of 
embolism 
Penetration via 
biological barriers  
Excretion by 
kidneys 
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A variety of smart DDS have been developed over the last years. Until now, some 
nanocarriers have been in reality approved in clinical applications, including liposomes, 
nano-suspension, polymer nanoparticles, microparticles, nanocapsule, micelles, etc.  
For example, the typical nanomedicines which are approved for clinical administrations 
are Doxil (Liposomal), Lipusu (Liposomal), and Abraxane (Nanoparticulate), to name a 
few [74-78]. Visudyne, a nanomedicine, was until now the only nanomedicine with 
nanoplatform concept licensed by the Food and Drug Administration (FDA) [79]. 
However, other DDS are yet at clinical stages. 
These approved formulations have been sufficiently evaluated and deeply optimized over 
the years by different attempts. One significant property of these promising nanocarriers 
relies on the simple formulations. Inconsistently, due to achieving smart properties, most 
of the developed smart DDS were designed with refined structures and formulations, 
which is complicated to scale up for industrial production. Therefore, design simplicity is 
still one of the critical points for successful drug carrier translation in these smart carriers. 
Besides, a considerable number of optimizations and improvements experiments are 
required for the realization of each stimulus from preclinical, experimental models to real 
clinical practice. Clinically appropriate formulations have to possess the properties of 
reproducibility, scale up or industrialize possibility, and verifiability. Accordingly, more 
attempts should be focused on the development of advanced attempts that can precisely 
control the preparation process, to generate nanocarriers with essential features, high 
batch-to-batch reproducibility, and industrialization practicality. The standard production 
methods and dosage control may finally expedite the translation of smart drugs from the 
bench to the industry. 
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2.5 Malaria, a fatal disease for human beings  
Malaria is caused by protozoan parasites of the genus Plasmodium [80-81]. Four of the 
>100 Plasmodium species infect humans and cause distinct disease patterns: P. 
falciparum (malaria tropica), P. vivax, P. ovale (both malaria tertiana), and P. malariae 
(malaria quartan). P. falciparum and P. vivax account for 95% of all malaria infections. 
Nearly all severe and fatal cases are caused by P. falciparum [82]. About 40% of the 
world’s population lives in malaria-endangered areas. Malaria is found in tropical regions 
throughout sub-Saharan Africa, Southeast Asia, the Pacific Islands, India, and Central 
and South America [83-84]. P. falciparum is found throughout tropical Africa, Asia, and 
Latin America. It is the predominant species in most areas. P. vivax is more common in 
India and South America but is also found worldwide in tropical and some temperate 
zones. P. ovale is mainly confined to tropical West Africa, while the occurrence of P. 
malariae is worldwide, although its distribution is patchy. Malaria is the most important 
infectious disease.  
 
Figure 12 Geographical distribution of malaria cases around the world (WHO, 2017) 
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Malaria murders between 1 and 3 million people annually, most of whom are children 
under the age of 5 and pregnant women. It is estimated that every forty seconds a child 
dies from malaria. P. falciparum malaria (also known as malaria tropica) can progress 
within a few days from uncomplicated to severe malaria with a lethal end-result in 10–
40% of all cases of severe malaria, depending on the time between the outbreak of the 
symptoms and curative treatment, as well as on the medical facilities for the management 
of complications [85-86]. Observed complications can include coma (cerebral malaria), 
respiratory distress, renal failure, hypoglycemia, circulatory collapse, acidosis, and 




Figure 13 Microscopic image of Anopheles mosquito body. [89]; [Permission: this is an open article 
distributed under the terms of the creative commons CC BY license, which permits unrestricted use, 
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2.5.1 Antimalarial agents  
Today, malaria is still the essential transferable infectious disease worldwide. 
Considerable success in achieving control over this mortal threat was achieved in the 
1950s and 60s through landscaping measures, vector control with DDT, and the 
widespread administration of chloroquine, the most crucial antimalarial agent ever.  
In the late 1960s, the final triumph over malaria was believed to be within reach. However, 
the parasites could not be destroyed because they developed resistance against the most 
widely used and affordable drugs of that time. Today, the number of malaria cases are 
on the rise and have gained record numbers. Powdered bark from the cinchona tree 
containing the plasmodicidal quinoline alkaloids quinine and quinidine was the first 
medicine to be used against malaria (Fig. 14). In 1856, chemist William Henry Perkins 
set out to synthesize quinine. His efforts resulted not in quinine (the first total synthesis 
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Chloroquine has been the most successful single drug for the treatment and prophylaxis 
of malaria [92-93]. Chloroquine is a safe and reasonably priced medication, and it was 
useful before resistant strains started to arise in the 1960s. It was one of the first curative 
choices recommended by the World Health Organization (WHO) Global Eradication 
Program. 
 
Figure 15 Chemical structure of antimalarial chloroquine 
 
Due to the massive use of chloroquine, resistant malaria strains have developed 
independently in four different regions and have successively spread over almost the 
entire malaria-endangered area. Today, more than 80% of wild isolates are resistant to 
chloroquine [94-96].  
 
2.5.2 Artemisinins and synthetic peroxides  
Extracts of the herbage known as sweet wormwood have been widely used in China for 
the treatment of fever for as long as a thousand years. In 1971 the active substance, the 
sesquiterpene lactone artemisinin (ACT), was isolated, which is used in China for the 
treatment of malaria since the 1970s. Artemisinin is a highly active antimalarial agent [97-
99]. 




Figure 16 Chemical structure of artemisinin 
 
A key structural characteristic of all artemisinins is the 1,2,4-trioxane substructure or, 
better explained, the endoperoxide, which is mandatory as a curative point for antimalarial 
activity. Despite the growing importance of artemisinins and serval kind of uses, their 
exact mechanism of action is till now unresolved and remains a matter of intense debate. 
It has been proposed that iron (II)-mediated cleavage of the endoperoxide bridge leads 
to the arrangement of different C-centered radicals, which may be primary or secondary 
(Fig. 16). Which, if not possibly both, of these radicals is the active species is unclear 
[100-102]. 
 




Figure 17 Mechanism of treatment of malaria by artemisinin in the presence of iron (II) ion 
 
Semisynthetic derivatives of artemisinin have been developed because artemisinin is only 
poorly soluble in water and oil. The Derivatives of artemisinins have been until now 
classified mainly in two groups: 1. First-generation, and 2. Second generation [103-105]. 
Semisynthetic artemisinins of the first and second generations all rely on a sufficient 
supply of artemisinin isolated from plants. Maximum extracted yields of artemisinin are 
commonly about 0.6 %. Until now, the herb Artemisia annua is cultivated in China and 
Vietnam. Due to the growing need resulting from the increased adaptation of artemisinins 
by more and more countries, the raw material is already in short supply. Despite current 
efforts to cultivate Artemisia in Africa as well, it remains a question as to whether 
increasing future needs will be met [106-109]. 




Figure 18 Chemical structures of artemisinin and some of its derivatives 
 
A common problem of the so-called first-generation semisynthetic artemisinins is their 
rapid biotransformation that results in a short half-life and the formation of the neurotoxic 
dihydroartemisinin. Much work has been invested in the development of second-
generation artemisinins. Methyl and ethyl residues of the first-generation semisynthetic 
artemisinins artemether and arteether have been replaced by numerous other residues, 
some of them carrying polar groups, as is the case with artelinate, to decrease the 
lipophilicity and enhance water solubility. 
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2.6 Artemisone, a more effective member of ACTs family 
Artemisone (ART) is a semi-synthetic 10-alpha-amino derivative of artemisinin (see 2015 
Nobel Prize in Physiology or Medicine). Artemisone was selected as a therapeutic product 
candidate based on properties that distinguish it from other artemisinin derivatives, 
including greater potency, lower predicted neurotoxicity, the total cost of treatment, better 
stability, half-life, and pH solubility. Notably, Artemisone relies on a non-DHA metabolic 
pathway which distinguishes it from currently used artemisinins. This feature may provide 
significant clinical advantages in terms of fighting resistance, blocking disease 
transmission, or treating severe and cerebral malaria [110-111]. Efficacies of ART against 
the malaria parasite are substantially higher than those of the current artemisinin or 
artesunate. Also, as opposed to most current artemisinins, it demonstrates low 
lipophilicity and negligible neuro‐ and cytotoxicity in in-vitro and in-vivo assays. Thus, the 
drug offers appeal for application in artemisinin‐based combination therapy. In 
comparative studies in- vitro against a panel of multidrug-resistant isolates of P. 
falciparum, ART is greatly more active than artesunate, chloroquine, and pyrimethamine 
irrespective of the resistance profile. Ex vivo bioassay displays an effective method for 
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3 Results and discussions 
 
3.1 PCL-b-MPEG as an effective biocompatible and biodegradable carrier 
The biodegradable diblock copolyester PCL16500-b-MPEG5000 (the subscript describes the 
Mn of the polycaprolactone (PCL) block and MPEG according to NMR analysis) (PCL-
MPEG) was synthesized according to Fig. 19, following standard protocols [114-115] with 
some essential modifications, by ring-opening of ε-caprolactone catalyzed by stannous 
octoate in the presence of α-methoxy-ω-hydroxy-poly (ethylene glycol) (MPEG) as a 
macroinitiator. The reaction terms are demonstrated in Table 4.  
 
 
Figure 19 Formation of block copolymers of polycaprolactone (PCL) and methoxy terminated 
polyethylene glycol (MPEG) 
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For purification of the polymer, after precipitation in n-pentane, the polymer was extracted 
with water to remove the water-soluble parts of the product, like the oligo PCL-b-MPEG 
and unreacted MPEG. The purified polymer showed a monomodal GPC curve (Fig. 20). 
The x-axis represents molar mass and y-axis intensity. 
 
 
Figure 20 GPC chromatogram of synthesized PCL16500-b-MPEG5000  
 
The isolated yields were in the order of 90–92% for the different synthesis attempts. The 
conventional chemical structure of PCL-MPEG was confirmed by observation of 
characteristic peaks of both MPEG and PCL in the 1HNMR spectrum. -OCH2-(protons of 
MPEG, 6/6’) and PCL (1) were observed at 3.61(s) and 4.03 (t) ppm, respectively. The 
other protons of PCL were obtained at 2.27 (t) ppm [CH2CH2C (O) O-, 5], 1.56−1.67 (t) 
ppm [-OCH2CH2CH2CH2-, 2; -C (O) CH2CH2CH2-, 4], and 1.29−1.40 (m) ppm [C 
(O)CH2CH2CH2CH2CH2O-,3] (Fig. 21). 
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3.2 Loading of ART in DDS based on electrospun structures as the carrier 
First, we studied the loading of nanofiber nonwovens (NFN) with ART and its release 
properties without and with additional coatings due to tailor the ART release profiles. The 
polymer applied for the preparation of ART-loaded NFN by electrospinning was the very 
well-known block copolymer polycaprolactone (PCL)16500-b-α-hydroxy-ω-methoxy-poly 
(ethylene glycol) (MPEG)5000 (PCL-MPEG). The polymer applied for the additional coating 
was poly(xylylene) (PPX), which provides established biocompatible coatings [116]. PCL-
MPEG was prepared by ring-opening polymerization, as demonstrated previously in 
detail. ART-loaded NFN were obtained by solution electrospinning of mixtures of PCL-
MPEG and ART in different compositions (0–20 wt.% ART).  
NFN with smooth fiber surfaces and an average fiber diameter of 220 ± 65 nm (for 
samples with contents of 12.5 wt% ART) were obtained (Fig. 22). The content of ART in 
NFN was quantified by 1H-NMR and high-pressure liquid chromatography (HPLC). While 
NFN with 12.5 wt.% of ART was homogenous (Fig. 22a), NFN with a more considerable 
amount of ART (20 wt%) showed the formation of ART crystals (Fig. 22b). The distribution 
of ART in NFN with 12.5 wt% ART was analyzed by energy dispersive X-ray analysis 
(EDX) by tracing sulfur of ART. The EDX showed the homogeneous incorporation of ART 
on the surface and cross-section of NFN (Fig. 22c, d). Consequently, the NFN samples 
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Figure 22. SEM and EDX images of ART loaded electrospun NFN. a) 12.5 and b) 20 wt% ART-loaded 
NFN. c) The surface and d) cross-section of ART-NFN with the content of 12.5 wt% ART 
 
 
Furthermore, the crystallinity of ART powder, polymer powder, and final product ART 
loaded NFN with the content of 12.5 wt.% ART was investigated by X-ray (Fig. 23). This 
study approved the crystallinity nature of ART and semi- crystallinity of the carrier (PCL-
MPEG). Furthermore, in the final product (ART loaded NFN with 12.5 % ART content), 
ART could be integrated mainly in the amorphous phase of the polymer. The final product 
showed only some reduced peaks (2θ: 7-12o) 




Figure 23 X-ray studies on ART-NFN, ART powder and PCL-MPEG powder 
 
3.3 Determination of drug content in nanofibrous DDS 
Two analytical methods could be applied during this project for identification as well as 
for quantification of drug content which was encapsulated or incorporated in polymeric 
DDS:  
1. Nuclear magnetic resonance spectroscopy (NMR) and 2. High-performance liquid 
chromatography (HPLC). In this project, HPLC was used mainly as the key device to 
quantify the drug contents in NFN, and all other polymeric carriers applied during this 
thesis. NMR was applied randomly to support the obtained results from HPLC. HPLC 
method could be validated during this project, and furthermore, NMR results could also 
confirm the validity of the HPLC method.  
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3.3.1 Determination of drug content in electrospun DDS by NMR 
NMR spectroscopy was applied to identify and quantify the ART content in drug-loaded 
samples as a supportive method (Fig.25 and Fig.26). This technique could recognize 
different hydrogen atoms in the chemical structure of ART, but two main peaks, first one 
at δ: 5.3 ppm (1H, s, H-1) and the second one at 4.2 ppm (1H, d, H-2) were employed as 
the most characteristic peaks to follow the presence of ART. A single signal at δ: 5.3 is 
used in this work as the unique peak for the quantification of ART content (Table 5). For 
the determination of ART content, each sample has been quantified by examining at least 
three NFN mats, and assay values were reported as the mean value ± standard deviation.  
 
Figure 24 1HNMR spectrum of pure ART in CDCl3. 
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content (% wt.) 
IntegralART/IntegralPCL-b-MPEG Exp. ART 
content (% wt.) 
Assay (%) ± 
SD 
NFN-formulation 1 14.3 4.15 14.26 99.70 ± 0.5 
NFN-formulation 2 12.5 3.61 12.41 99.28 ± 0.5 
 
It should be noticed that for all assay determination studies, a previously calibration line 
(Fig. 26) obtained from the standard calibration line was used as the reference.   
 
Figure 25 1HNMR spectrum of ART loaded NFN with the drug content of 12.5 wt. % 






Figure 26 Calibration line of standard solutions of ART and polymer in CDCl3, relative standard deviation 
(RSD) values were for all experiments below 2% 
 
3.3.2 Determination of drug content in electrospun DDS by HPLC 
HPLC instrument was equipped with an Eclipse XDB-C18, 4.6 x 150 mm, 5 μm column. 
The acetonitrile (50 % v), H2O (30 % v), and methanol (20 % v) was used as mobile phase 
with a UV detector at λ: 260 nm. The temperature of the column was set to 35°C, the flow 
rate of the mobile phase was 0.8 ml/min, and the injection volume was 20 μl. The different 
NFN were dissolved in the mobile phase, and encapsulated ART was readily dissolved 
in the solvent after stirring at room temperature for estimation by HPLC. For this purpose, 
at least three samples of ART loaded products were dissolved in the mobile phase and 
then analyzed at λ: 260 nm by HPLC (Fig. 27). The assay values were achieved by 
comparison between data obtained from ART loaded samples and the standard data 
which were gained from standard solutions (Fig. 28). These results were compared with 
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results from quantitative NMR. This comparison confirmed that all assay data are 
reproducible and repeatable in both methods. 
 
   Table 6 Determination of ART contents by HPLC 
ART loaded sample Theo. ART content 
(% wt.) 
Exp. ART content 
(% wt.) 
Assay (%) ± SD 
NFN-formulation 1 14.3 14.26 99.70 ± 0.5 




Figure 27 HPLC chromatogram of eluted ART from NFN in the mobile phase 
 




Figure 28 Validation of HPLC method based on repeatability for different solutions. RSD values were for 





3.4 Studies on drug release behaviors of ART from NFN 
HPLC studied the in vitro ART release characteristics from NFN with PBS (phosphate-
buffered saline) of pH 7.4 as release test medium (Fig. 29). The complete release of ART 
within 5 hours in PBS solution was only about 13.23 ± 0.036 wt.%. The explanation for 
this relatively low and slow release of ART from NFN is its limited solubility in PBS: the 
maximum solubility of ART in PBS as determined by HPLC analysis was only 0.074 ± 
0.002 mg mL−1. Even with an extended-release time of several days (not shown here) a 
100 wt.% Cumulative ART release was never observed. The solubility and release of ART 
were enhanced significantly to 1.79 ± 0.01 mg mL−1 with 1% w/v of sodium lauryl sulfate 
(SLS) in water as release medium (pH ~ 7.4, adjusted with sodium bicarbonate). SLS 
acts naturally as a surfactant for ART, as it is known to enhance solubility for other 
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hydrophobic drugs [117-119]. Consequently, fast and 100 wt.% the release of ART from 
NFN could be achieved by using the SLS medium in less than 1 h, with more than 70% 
drug released in about 30 min (Fig.30). 




































 ART release from NFN
medium: PBS buffer
 
Figure 29 In vitro cumulative release of ART from uncoated NFN, in an aqueous solution containing PBS 
buffer, ART content for all samples: 12.5 wt% and mean quantities of ART in all samples: 5.55 ± 0.34 mg. 
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 ART release from NFN
medium: 1% w/v SLS in water
 
Figure 30 In vitro cumulative release of ART from NFN in an aqueous solution containing 1 w/v % SLS, 
ART content for all samples: 12.5 wt% and mean quantities of ART in all samples: 5.55 ± 0.34 mg. 
 
 
3.5 Degradation of ART in an aqueous environment 
We also carried out stability studies of ART powder to have the basis for comparison. In 
our studies, at 37 ± 0.5 °C, almost 10 wt.% of the ART powder was degraded in 1% w/v 
SLS at pH 7.4 ± 0.1 in the first 5 h. Whereas, ≈86 wt.% of ART was decomposed in 
contact with SLS medium after 19 d (Fig. 31). The appearance of new signals in HPLC, 
in combination with the decline of the signal for ART, became evident by comparison of 
the HPLC traces of a fresh ART solution, with a solution after storage for 308 h. The 
dissolved drug was analyzed by HPLC for checking the stability (Fig. 32). The instability 
of ART in aqueous media is one of the known problems giving degradation products of 
unknown toxicity and wastage of the valuable drug. 
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Degradation of ART in aqueous medium 
 
Figure 31 Decomposition of ART in aqueous medium composed of 1 % w/v SLS, pH of medium: 7.4 ± 0.1 
and temperature: 37 ± 0.5 oC. Concentration of ART: 1.03 ± 0.02 mg/ml. All tests were repeated three times. 
RSD values for all experiments were below 2 %. 
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3.6 Managing of the rate of ART release from NFN by coating 
HPLC studied the in vitro ART release characteristics from NFN with PBS (phosphate-
buffered saline) of pH 7.4 as the release test medium. The complete release of ART within 
5 h in PBS solution was only about 13.23 ± 0.036 wt.%. The explanation for this relatively 
low and slow release of ART from NFN is its limited solubility in PBS; the maximum 
solubility of ART in PBS as determined by HPLC analysis was only 0.074 ± 0.002 mg 
mL−1. Even with an extended-release time of several days (not shown here) a 100 wt.% 
Cumulative ART release was never observed. The solubility and release of ART were 
enhanced significantly to 1.79 ± 0.01 mg mL−1 with 1% w/v of sodium lauryl sulfate (SLS) 
in water as a release medium. SLS acts obviously as a surfactant for ART, as it is known 
to enhance solubility for other hydrophobic drugs.  Consequently, fast and 100 wt.% the 
release of ART from NFN could be achieved by using the SLS medium in less than 1 h, 
with more than 70% drug released in about 30 min. 
To overcome the burst release of ART and the problem of the instability of ART in contact 
with media, we applied the CVD coating of PPX of different thicknesses (68–870 nm) on 
the ART containing NFN. 
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 NFN without PPX coating
 76.5 nm PPX
 205.5 nm PPX
 698 nm PPX
 878.5 nm PPX
 
Figure 33 In vitro cumulative release of ART from uncoated and PPX coated NFN in an aqueous solution 
containing 1% SLS, ART content for all samples: 12.5 wt% and mean quantities of ART in all samples: 5.55 
± 0.34 mg. 
 
Two other coating agents were also used for the fabrication of biocompatible nanofibrous 
structures: 1. Aqueous dispersions of PCL-MEPG and 2. In water dissolved Gelatin. 
Coated membranes were produced by the dip-coating technique. Both of the coatings 
could reduce the rate of drug release from nanofibrous mats. The more retarded release 
could be earned by PCL-MPEG coated fibers because of its dispersity but not solubility 
nature in water compared to the solubility of gelatin.  
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The kinetic of the drug release from coated mats are presented below (Fig. 34). All these 
attempts could confirm this reality that the coatings are an excellent device to overcome 
the burst release kinetics from nanofibrous mats and to control the rate of the drug 
release. The dispersion coatings showed more retarded release compared to gelatin 
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 NFN coated in (1:1) Dispersion
 NFN coated in (1:2) Dispersion
a
 
































 NFN coated in sol. 1% Gelatin
 NFN coated in sol. 10% Gelatin
b
 
Figure 34 In vitro cumulative release of ART from uncoated and coated NFN in an aqueous solution 
containing 1% SLS, ART content for all samples: 12.5 wt.% and mean quantities of ART in all samples: 
5.0 ± 0.5 mg. 
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3.6.1 Coating with PPX 
PPX is a biocompatible polymer, which has been used successfully as a coating on films 
for the retardation of the release of dexamethasone and NFN for the retardation of 
enzyme release [116]. The particular advantages of the CVD coating by PPX are very 
mild conditions (no solvent, no catalyst, room-temperature processing) and the formation 
of conformal, pin-hole free coatings. As expected, the PPX coating retarded the ART 
release, and we observed a change from burst release (for uncoated fibers) to a linear 
ART release profile depicting a delay that depends on the PPX coating thickness (Figure 
35). 
 
Figure 35 SEM images of PPX coated NFN with thicknesses from 68.5 to 870.5 nm used for in vitro 
release studies 
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3.6.2 Coating of NFN by dip-coating in the aqueous solution of gelatin and the 
aqueous dispersion of PCL-b-MPEG 
Dip coating is the precision-controlled immersion and withdrawal of any substrate into a 
reservoir of liquid for the settlement of a layer of material. Many chemical and 
pharmaceutical research projects in academia and industry make use of the dip-coating 
technique. 
In theory, dip coating is straightforward. The sample is perpendicularly dipped into a 
solution or dispersion. The sample is let to stay immersed in the solution to allow some 
time. After this, the sample is withdrawn out from the solution and let to dry. 
The SEM images of ART loaded fibrous structures are demonstrated in (Fig. 36 a-e). It 
can be observed that by the addition of coating agents on the surface of membranes, the 
thickness of the resulting fibers has been increased. As showed, there were no detectable 
drug aggregates on the surface of NFN. A tendency to form the films from fibrous 
structures could be observed by increasing the concentration of coating agents and by 
fabrication of the structures wither thicker diameters (Fig. 36 c, d). 
The EDX measurements confirmed the homogeneous distribution of ART in membranes 
(Fig. 36, f-e). The sulfur atom of medication was used as an indicator to follow the 
locations of encapsulated ART in nanofibrous structures. It should be noticed that EDX 
was applied here as a supporting method to investigate the homogenous distribution of 
ART in the carrier. Generally, the homogenous distribution of ART was investigated 











Figure 36 Morphological studies: a) original NFN, 193.82 ± 72.27 nm. b) NFN coated with 1% gelatin, 
302.84 ± 73.49. c) NFN coated with 10% gelatin, 493.17 ± 89.88. d) NFN coated with dispersion 1, 
1136.46 ± 336.04. e) NFN coated with dispersion 2, 461.74 ± 134.57. EDX-mapping of ART: f) surface of 
original ART loaded NFN and g) its cross-section.  
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3.7 Studies on drug release behaviors of ART from drug-loaded films 
By entrapment of ART in pressed films, the rate of the drug release could be significantly 
reduced. Furthermore, the burst release, which typically can be observed during the drug 
release from the drug-loaded nanofibrous structure, could be reduced by the fabrication 
of such ART loaded films. While 100% release could be achieved from nanofibrous 
membranes during 3 hours, approx. 40% drug could be released from the film (thickness 
of 500 ± 20 μm) during 5 hours (Fig. 37). Additionally, as to be observed, the thickness of 
the carriers plays an essential role in controlling the rate of the drug release. More 
retarded drug release could be achieved by thicker films.  






























 NFN mat, thickness: 100  10 um
 Film, thickness: 100  10 um 
 Film, thickness: 500  20 um
 
Figure 37 ART release from films and fibrous structures in an aqueous solution containing 1% SLS, ART 
content for all samples: 12.5 wt.% and mean quantities of ART in all samples: 5.0 ± 0.5 mg. 
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Morphological studies of the drug-loaded films showed the non-smooth surfaces because 
of the presence of crystalline ART pressed in films (Fig. 38a). Anyhow, the EDX 
measurements confirmed the homogenous distribution of ART in polymeric films not only 





Figure 38 Morphological studies of ART loaded films (thickness: 500 ± 20 µm), ART content for all 
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X-ray tests were performed to determine the physical status of ART in films. As showed 
in Fig. 39, PCL-MPEG as a semi-crystalline polymer, demonstrated detectable peaks at 
2θ: 21.6o and 23.8o. ART also showed a crystalline structure so that the clear signals at 
12.30o, 16.80o, 17.50o and 18.40o could be detected (Fig. 39). Interestingly in WAXS 
patterns of ART loaded NFN, no main characteristic signals of ART could be observed. It 
means ART was no longer present as a crystalline material and had been converted 
mainly into an amorphous state. The pressed films, unlike the electrospun nonwoven, 
showed visible signals composed of standard characteristic signals of both ART and 
polymer. The films could keep their crystalline structures because, during the film 
pressing, they have enough time to be recrystallized, unlike the electrospinning process.        
 










Figure 39 Morphological studies of ART loaded films (thickness: 500 ± 20 µm), ART content for all 
samples: 12.5 wt.% 
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3.8 Degradation studies on NFN and films fabricated from PCL-MPEG 
The enzymatic degradation experiments of polymeric carriers showed interesting 
behaviors (Fig. 40). The films showed higher stability in the enzymatic environment 
(Esterase EL-01) compared to nanofibrous structures. By increasing the thickness of 
films, they could be more resistant. Mainly, the films were till 3 hours, relatively stable 
against degradation but after 3 hours, degradation was accelerated after the first bulk 
degradation and incorporation of water in films. Unlike this mechanism, NFN mats 
showed a linear degradation behavior. It can be interpreted because of porous structures 
of NFN and higher water uptake capacity. More retarded degradation nature of films 
supports more retarded drug release behavior of these carriers additionally.      



























 Film, thickness: 500  10 um
 Film, thickness: 100  10 um
NFN mat, thickness: 100  10 um
 
Figure 40 Enzymatic degradation of the polymeric carrier (matrix) 
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3.9 Water uptake by NFN and films fabricated from PCL-MPEG 
The determination of swelling ratios of matrix structures (NFN and films without drug) can 
be observed in Fig. 41. The water uptake ability by NFN higher compared to the films. 
This could be interpreted probably because of a large amount of water retained in the 
fibrous pores and also due to the higher surface area of NFN. Interestingly, by increasing 
in the thickness of the films, the swelling ratio values were decreased. All these findings 
support the more retarded drug release from films, particularly thick films. The swelling 
results were calculated according to the following equation for each sample: 
      m2 - m1 
                                         Swelling ratio (%): ---------------- x 100 
                                                                              m1 
m2 represents the weight of the scaffold in wet condition and m1 the weight of the same 
dried scaffold.  























Figure 41 Comparison between swelling ratios of matrix 
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3.10 Studies on drug release behaviors of ART from drug-loaded 3D structures 
In this study, the ultralight sponge fabricated by an acrylate copolymer [poly(methyl 
acrylate(MA)-co-methylmethacrylate(MMA)-co-4-methacryloyloxybenzophenone 
(MABP) was used as 3D carrier. Two different densities, 3.5 and 6 mg/cm3 of this sponge 
were explicitly considered for drug loading and also studies on the drug release. The 
applied sponges are shown here as d3.5 and d6 (d3.5= sponge with density of 3.5 mg/cm3 
and d6= sponge with density of 6 mg/cm3).The sponges included pores with a size of 
about 100 μm and pores of a few micrometers, between the fiber interconnections (Fig. 
42 A, B). High ART loading was accomplished with sponge d6, which is shown in Fig. 42 
C, D.  Generally, the mechanical properties of sponge d3.5 due to its very low density 
was too low for the applied loading procedure. Regarding to the much better mechanical 
stability of d6, most of the following experiments were focused on the d6.  
 
Figure 42 Cross-sectional SEM images of as-prepared sponges d3.5 (A) and d6 (B), and d6 after loading 
with ART (C, D). 
Controlled Release of Antimalarial Artemisone by Macromolecular Structures 
69 
 
In parallel with the increased concentration of the ART solution from 14 to 25 mg/mL, the 
ART loading amount of d6 (2.51 mg) was changed from approx. 4. 7 to 6.6 mg, meaning 
that the loading capacity was increased from 1870 to 2640 mg/g (ART loading ratio 
increasing from 1.87 to 2.64) (Table 7).  
Table 7 Change of ART Loading Capacity of d6 by Using tert-Butanol Solutions of ART with 
Concentrations of 14 and 25 mg/mL 
Concentration of 
ART in t-butanol 
(mg/ml) 




















Mean: 1.87 ± 0.11 


















Mean: 2.64 ± 0.07 
 
Overall, the macroporous sponge had very high ART loading capacity. However, ART 
was loosely placed on the surface of the fibrous network of the sponges or just settled in 
the pores, which would lead to losses induced by mechanical stress and to burst release 
of ART during the initial release process. 
The small crystals of ART could be dissolved in the first stages of the release process. 
This behavior caused a burst release, seen in the initial 20 min. After that, the bigger 
particles of ART crystals gradually dissolve, initiating the retarded release. By loading the 
drug in the fibrous sponge with small density (3.5 mg/cm3, d3.5), 100% of the drug was 
released within the first hour. The ART loaded sponges were treated by freeze-drying that 
could cause ART recrystallization into small crystals with a size of several micrometers, 
which led to the fast dissolution in the liquid medium and the fast burst release. 
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In comparison, when the sponge with higher density (6 mg/cm3, d6) was used, a more 
retarded release could be achieved: about 50 and 87 wt. % of ART was released in 2 and 
5 h, respectively. The different drug release profiles from the sponges (d3.5 and d6) could 
be related to the much higher specific pore volume (SPV) of d3.5 compared to d6, which 
facilitated the mass transfer of ART to the liquid medium. 









 Density: 3.5 mg/cc
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3.11 Studies on drug release behaviors of ART from drug-loaded microparticles 
In the last parts of this project, several kinds of carriers were used to deliver the 
antimalarial ART. As demonstrated previously, several kinds of kinetics from burst release 
to retarded release behavior could be achieved. Investigation of the release behavior of 
a hydrophobic drug like ART is essential to manage the drug release. Microparticles, as 
another kind of carrier, can also play an essential role in controlling the drug release.  
In this part of this project, we focused on gelatin as the biocompatible and soluble 
biopolymer to fabricate ART loaded microparticles. A spray drying technique could 
produce gelatin microparticles. This technique is especially well known and applicable to 
solubilize the hydrophobic drugs because, by this technique, the size of drug molecules 
can be managed in a wide range from few nanometers to micrometers. Furthermore, the 
re-crystallization of the drug molecules is de facto so fast that the crystallinity behavior of 
substance can be changed and generally moderated. Therefore, the hydrophobicity of 
the drug molecule can also be moderated, and a shift in the solubility nature of the drug 
can be observed. Finally, the drug molecule will be more soluble in the aqueous 
environment after spray-drying.      
This behavior could be easily observed by ART loaded gelatin particles in this project. In 
this work, particles with 2-4 µm could be fabricated from aqueous solutions, and during 
approximately 40 minutes, the 100 %-drug release could be earned (Fig. 44). This release 
behavior can be fascinating, especially for nasal administrations.   
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 ART release from MP
 
Figure 44 In vitro ART release from the ART loaded microparticles  
 
 
Figure 45 SEM images of ART loaded gelation microparticles  
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3.12 Administration of ART loaded macromolecular carriers 
ART loaded macromolecular scaffolds were administrated in mice models in biological 
labor to study the curative effects of these structures in frame of the in vivo studies. These 
studies were performed by Prof. Jacob Golenser’s research group at Hebrew University 
of Jerusalem. The results obtained from these in vivo studies are reported in this thesis 
after discussion with Prof. Golenser and presented here as supporting information. 
 
3.12.1 Administration by implantation 
Mice were injected intraperitoneally with Plasmodium berghey ANKA. Inserts (including 
films and NFN) containing artemisone or blank inserts were introduced subcutaneously 
on different days post or before infection, as indicated (n= number of mice in the group. 
D= dead.) Death of mice with parasitemia below ~20% parasitemia accompanied by a 
typical disease is considered as the death of cerebral malaria (CM). All control mice died 
of CM. Each line represents a single mouse. 
 
3.12.2 In vivo studies of ART loaded films 
ART loaded films were applied to insert into the infected mice after 1- and 6-days 
infection. The results have been demonstrated in Fig. 46. As shown, all infected mice 
were cured, even those who had 6-days infection. These results confirmed that a dose of 
2 mg ART is a curing dose for the treatment of infected mice under defined in vivo 
conditions. As expected, films with approx. 500 µm thickness support the retarded release 
and furthermore, the loaded ART can be stabilized longer and, therefore, longer effective 
against infection if it is entrapped in thick films. 





Figure 46 Insertion of ART loaded films after 1- and 6-days post-infection, the dose of ART: 2 mg 
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3.12.3 In vivo studies of ART loaded NFN  
ART loaded NFN were applied to insert into the infected mice after 2- and 7-days 
infection. The results have been demonstrated in Fig. 47. As shown, all infected mice 
were cured after 2 days of infection. However, the infected mice which had 7-days 
infection could not be cured anymore. These results confirmed that loaded 2 mg ART 
were not enough to rescue the infected mice.  
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Experiments were repeated for ART loaded films with 2 mg ART on mice with 7dayspost-
infection (Fig. 48).  Interestingly, after the insertion of ART loaded films, the mice could 
be partially cured, and infection could be decreased meaningfully. The life of the infected 
mice could be prolonged, and even 2 mice from 5 mice could be cured. Therefore, these 
studies confirmed that 2 mg ART could be an effective dose against infection. These 
studies confirmed that the more retarded release obtained from thick films supports the 
curing process during a prolonged release period since ART loaded NFN, which produce 
faster release are the better choice for the treatment of infected mice, which are freshly 
(after 1- or 2-days post-infection) infected.  
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3.13.1 Administration by infusion therapy  
The main issues with artemisinins are low bioavailability, short half-life, low solubility, and 
stability in an aqueous medium. The decomposition of artemisinins in the aqueous 
medium is critical as the physiological effect of the decomposition products is uncertain.  
ART is rather expensive and cannot be stored in the form of liquid formulations for delivery 
purposes, ruling out simple infusion formulations as one of the ways of controlled drug 
delivery. Although there are some efforts in the literature to provide controlled release of 
artemisinins in vitro from nanovesicles and solid lipid particles, due to the complexity of 
the situation, the systems are far away from any practical utility. Due to the complexity of 
the problem and restrictions imposed by the nature of the drug, no simple solution is 
applicable. This is the general problem in the field of drug delivery wherein Vitro studies 
using various drug delivery carriers, including nanofiber nonwoven (NFN) made by 
electrospinning, are indicative of applicability but not transferable to actual in vivo 
applications. 
To solve this problem, we decouple the programmed drug release from the physiological 
environment. In this work, we suggest that the combination of the advantage of precise 
and reproducible programmed release from NFN in vitro with the drug delivery infusion 



















Figure 49 The depiction of the concept of programmed drug release from drug-loaded polymeric nanofiber 
nonwoven carrier placed in the drip chamber of an infusion system [120]; [Creative Commons Attribution 
License; Permission is not required for academic or commercial reuse.] 
 
In our system, the control over drug release is achieved outside the physiological 
environment by placing ART-loaded NFN in the drip chamber of an infusion system, which 
can release ART in an adjustable manner. The ART-loaded NFN were additionally coated 
with the biocompatible polymer poly(p-xylylene) (PPX) by chemical vapor deposition 
(CVD) to control the release profile and stability of the drug in infusion medium by 
confinement. Our drug-delivery concept also takes care of the low solubility of ART in 
aqueous media by using an infusion medium with appropriate surfactant (Tween 80) 
helping the release of the hydrophobic drug. The maximum solubility of ART could be 
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increased linearly by increasing the quantity of the surfactant (Tween 80), as shown in 
additional experiments (Fig. 50). 


























Amount of Tween 80 (% wt.)
y = 0.216x + 0.0807
R² = 0.9991
 
Figure 50 Increasing the solubility of ART in the aqueous media by addition of Tween 80 as a 
biocompatible solubilizer. 
 
Our concept and setup are rather simple and could be manufactured under sterile 
conditions by the placement of the ART loaded NFN in the drip chamber of the infusion 
set. Programming of ART release and the dose was accomplished by the management 
of the flow rate, the formulation of the infusion medium, and the amount of ART in NFN 
placed in the drip chamber. 
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First of all, the amount of drug released and release profile could be controlled by 
changing the flow rate of the infusion medium (0.9% w/v saline solution with 1 wt.% 
biocompatible surfactant (Tween 80)) from the ART-loaded NFN. The lower flow rate 
(0.083 mL min−1) avoided burst release, and the release of the drug was completed in 
≈5.5 h. Whereas, the higher flow rate (0.23 mL min−1) led to the release of more than 20 
wt.% a drug already in the first 30 min and the drug release was completed in ≈3 h (Fig. 
51a). 
Further, at a constant flow rate of the infusion medium, the drug release profile could be 
changed by using different concentrations of surfactant in the medium (Fig. 51b). The 
amount of Tween 80 affects the solubility of the drug and hence the release profile. 
Therefore, the maximum dose of ART eluting out could be well controlled by the amount 
of Tween 80 in the infusion medium, which is critical as overdoses of ART would be 
harmful. The released drug could be sustained at a constant amount for more than 5 h 
on using the low concentrations of Tween 80 (0.5 wt.%) at a flow rate of 0.083 mL min−1 
besides avoiding the burst release. In this case, a relatively linear increase in the 
cumulative release curve from 1 to 6 h could be observed (Fig. 51c). The sustained 
release of ART could be further extended from ≈7 to 14 h by increasing the mass of drug-
loaded NFN in the drip chamber (Fig. 51c).  
The release profile could also be changed by an additional PPX coating on the NFN 
without a change of the amount of ART in the NFN (Fig. 51d). Under similar conditions 
(infusion medium: 0.5 wt.% Tween 80; flow rate: 0.083 mL min−1), the drug release 
experiment using ART powder in the drip chamber of an infusion system led to not the 
controllable release of ≈30 wt.% drug in 15 h. The release curve showed a fast release 
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regime in which about 20 wt.% of the drug was released in about 7 h, followed by a 
prolonged release. The faster release, in the beginning, might be due to the dissolution 
of small ART crystals. The dissolution of hydrophobic drugs is dependent on the crystal 
size; smaller crystals dissolve faster than more significant. 
 























 Flow: 0.23 ml/min
 Flow: 0.083 ml/min
1 wt. % Tween 80 in IV medium
  ART in NFN: 5.49 ± 0.66 mg 
a
 
     






















 1 wt. % Tween 80 in medium
 0.5 wt. % Tween 80 in medium
              Flow: 0.083 ml/min
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 Lower dose of ART in NFN: 5.40 ± 0.10 mg 
 Higher dose of ART in NFN: 10.86 ± 0.10 mg
 Higher dose of ART powder: 10.86 ± 0.10 mg










































 PPX coated ART-NFN
Flow: 0.083 ml/min, 1 wt. % Tween 80




Figure 51 The programmed release of ART from NFN by infusion system, ART content for all formulation: 12.5 
wt.%. a) The effect of flow rates on ART release from NFN at two different flow rates of 0.083 and 0.23 mL min−1, 
the medium contains 1 wt% Tween 80. Mean amounts of ART in NFN: 5.49 ± 0.66 mg. b) The effect of the 
amount of Tween 80 on ART release from NFN at the adjusted flow rate of 0.083 mL min−1, but intravenous (IV) 
media include 0.5% and 1% Tween 80. Mean amounts of ART in NFN: 5.68 ± 0.39 mg. c) The effect of doses of 
the drug on release behavior of ART from NFN, lower doses: 5.40 ± 0.10 mg drug and higher doses: 10.86 ± 
0.10 mg, the comparison was also done by putting 10.86 mg of ART powder in the drip chamber (blue curve) 
and d) the effect of PPX coated layer with a thickness of 68.5 ± 10 nm on ART release from NFN, mean amounts 
of ART in NFN: 6.42 ± 0.64 mg.  
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4. Experimental part 
 
4.1 Materials  
ε- Caprolactone (CL) was purchased from Alfa Aesar and was dried over calcium hydride 
(Merck Co.) for 24 hours and purified by vacuum distillation. α-Hydroxy-ω-methoxy-
poly(ethylene glycol) (MPEG, Mw: 5000) from Aldrich Co. was dried out in a vacuum oven 
at 40 °C for 2 hours. The poly(ethylene oxide) (PEO, Mw: 900,000) was purchased from 
Acros Co., and it was used in dried form after drying in a vacuum oven at 40 °C for 2 
hours. Stannous octoate [Sn(Oct)2] and sodium dodecyl sulfate (SLS), Tween 80, 
pyridine, THF, methylene chloride from Sigma-Aldrich and formic acid from Fluka were 
used as received. Parylene N was used as received (Specialty Coating Systems, SCS). 
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4.2 Synthesis of PCL16500-b-MPEG5000 
The biodegradable diblock copolyester PCL16500-b-MPEG5000 (the subscript describes 
the Mn of the polycaprolactone (PCL) block and MPEG according to NMR analysis) (PCL-
MPEG) was synthesized according by ring-opening of ε-caprolactone catalyzed by 
stannous octoate in the presence of α-methoxy-ω-hydroxy-poly (ethylene glycol) (MPEG) 
as a macroinitiator. The reaction was started with 13.95 gr caprolactone and 4.65 gr 
MPEG. The mixture was heated up to 130 oC, and then 30 µL catalyst had to be added 
to the mixture. Finally, the mixture started to form a high viscose product, which was 
cooled down to room temperature after 3 hours as the reaction time.  For purification of 
the polymer, after precipitation in n-pentane, the polymer was extracted with water to 
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4.3 Degradation studies of ART in an aqueous environment  
The degradation studies were carried out by putting a definite amount of ART powder in 
1% w/v SLS at 37 ± 0.5 °C. The amounts of ART were quantified before incubation, and 
then all solutions were stored in a thermostatic incubator at a temperature of 37 ± 0.5 °C 
and shaken at 50 rpm. 1 ml of each solution was taken out and, finally, the dissolved 
amounts of ART were quantified by the HPLC method, which was described previously. 
All experiments have been repeated three times, and mean data have been reported in 
this work. Relative standard deviation (RSD) for all experiments was below 2%, and they 











Figure 52 Change in the appearance of ART powder after two weeks of stress under a relative humidity 






Storage at rel. humidity approx. 60% 
and temperature of 37 ± 0.5 °C  
 
Clearance: from white to yellow 
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4.4 Fabrication of ART loaded NFN 
Drug loaded polymeric solutions composed of 15 wt. % PCL-MPEG, 2.5 wt. % pyridinium 
format (PF) and different amounts of ART in methylene chloride (MC) were prepared. 
ART quantities could be variable due to the fabrication of different drug-loaded samples 
with different contents of the drug. PF has been produced by mixing of 1:1 (mol: mol) 
pyridine and formic acid. The mixtures were protected from light and stirred at least for 5 
hours at room temperature to form homogenous solutions. The solutions were 
electrospun with a voltage of 30 kV at a distance of 15 cm and a flow rate of 1.33 ml. hr-1 
on aluminum foil collecting electrode. An air humidifier controlled the humidity at 18–25%, 
and the temperature was adjusted to 20-22 °C. PF was added to the electrospinning 
solution for control of the electric conductivity of the formulation. During electrospinning, 
PF evaporates as pyridine and formic acid and cannot be traced anymore in the deposited 
ART containing NFN. The increase in electrical conductivity by the addition of PF caused 
a significant reduction of bead formation. The integrity of ART after electrospinning was 
verified by solution NMR. 
     
 
Figure 53 Fabrication of ART loaded NFN by electrospinning 
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4.4.1 Coating of ART loaded NFN by PPX 
PPX coating was done by lab coater 2010 (SCS) using [2.2] paracyclophane (Parylene 
N) as a precursor, according to Gorham’s method. ART loaded nanofibrous mats with the 
different thicknesses could be fabricated based on this method and also an internal 
calibration method.   
 
 

















Figure 54 PPX coater machine and a PPX-coated NFN mat 
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4.4.2 Coating of ART loaded NFN by dip-coating 
One day before the coating, all weighed NFN samples were dried out in freeze-dryer and 
put in a desiccator. For the preparation of gelatin-coated NFN, each scaffold was dipped 
in the solution of gelatin (1 % and 10 % w/v in distilled water) for 20 seconds. After that, 
the excess coating solution droplets were wiped off from the surface of fibrous mats by 
glass slides. The same method was also applied for the production of dispersion coated 
NFN by the exception of some differences. In this case, instead of 20 seconds, the 
samples were dipped in dispersion for 10 seconds. Instead of a gelatin solution, the 
dispersions of PCL-MPEG in water by two different ratios were used. The initial dispersion 
involved 15 wt.% PCL-MPEG, 2.5 wt. % PEO (900,000 g/mol) in water. This dispersion 
was produced in this work according to previously reported work [114]. For the preparation 
of two dip-coating emulsions, the dispersion was added by two different ratios to water, 
1:1 (dispersion 1) and 1:2 (dispersion 2) (w/w, dispersion: water). The mixtures were 
stirred over the night. 
   
Figure 55 Preparation of a dip-coating solution containing an aqueous dispersion of PCL-MPEG 
 
Controlled Release of Antimalarial Artemisone by Macromolecular Structures 
90 
 
4.5 Fabrication of ART loaded Films 
Block polymer PCL-MPEG was synthesized according to a previously described 
procedure. Block copolymers of PCL-MPEG were fabricated by different ratios of PCL: 
MPEG. To create a homogeneous mixture of PCL-b-MPEG and artemisone, different 
ratios of both compounds were dissolved in small amounts of tetrahydrofuran (THF; p.a. 
≥ 99.9%). After all, particles were dissolved, the solvent was completely evaporated. 
Using a heat press at 65 °C the mixture was pressed into a polytetrafluoroethylene matrix 
(internal size about 0.5 ×10 × 20 mm3) and then cooled down to room temperature under 
a second press at about 20 °C. After 2 min pressing, the templates were taken out and 
cooled down to 20 °C. The obtained films had a thickness of 500 ± 20 μm. This protocol 
was also used for the production of other films with 100 μm thickness by using other 
shaping templates (internal size: 0.1 x 10 x 20 mm). The films produced by these 
templates had average dimensions of 100 ± 10 μm.   
 
      
Figure 56 Heat-presser machine for fabrication of drug-loaded films 
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4.6 Enzymatic degradation of NFN and films fabricated from PCL-MPEG 
The enzymatic degradation was made by cutting the films, and NFN mats into the small 
pieces with the same dimension, and the weight of each piece was recorded (m1). All 
samples were dried out before recording the initial weight values. Then, each sample was 
placed in the vial, which was filled by a medium made of 4 ml PBS-buffer and 0.35 ml 
(containing 9 mg enzyme) of enzyme solution (Esterase EL-01). All vials were transferred 
into a shaking incubator so that the incubation took place for the specified time at 37 ± 
0.5 °C and 50 rpm shaking speed. The time started with the input of the enzyme and 
ended with the removal of the media. After removing the media, the samples were washed 
several times with distilled water and freeze-dried over the night. After drying, all samples 
were weighed again (m2) to get their mass-loss, according to bellow’s equation: 
                                     m2 
                                     remained residual mass (%): --------- x 100 
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4.7 Water uptake by NFN and films composed of PCL-MPEG 
To investigate the swelling behaviors of the carriers, the ART loaded NFN and films with 
known weights (m1) were put in vials containing 10 ml distilled water (pH: neutral) and 
incubated for 24 hours at 37 ± 0.5 oC. Finally, the water droplets on the surfaces of 
samples were removed with the pieces of paper, and finally, the weight of the wet samples 
was recorded (m2). The swelling results were calculated according to the following 
equation for each sample: 
                   m2 - m1 
                                         Swelling ratio (%): ---------------- x 100 
                                                                              m1 
 
4.8 Loading of ART in ultralight sponges as 3D structures  
The ultralight sponges were chemically prepared from poly (methylacrylate-co-methyl 
methacrylate-4-methacryloyloxybenzophenone). 
For the loading of drug in 3D scaffolds, ART (CIPLA, India) was dissolved in tert-butanol 
in concentrations of 14 and 25 mg/mL. Then, 1 mL of drug solution was filled in a syringe 
and slowly dropped onto the precut d3.5 and d6 (10 × 10 × 5 mm) at room temperature 
(22 ± 1 °C) until the whole sponge was wetted by the solution. Drug-wetted sponges were 
put in liquid nitrogen for freezing and drying in vacuum for 24 h by a freeze-dryer. The 
amount of ART in the sponge was determined by a high precision analytical balance with 
the readability of 0.01 mg. 










4.9 Fabrication of ART loaded microparticles by spray-drying 
1.93-3.96 g gelatin was dissolved in 100 ml distilled water. The solution was stirred for 
several hours so that a homogenous solution could be gained.  
Parallel, a saturated solution of ART in an aqueous medium including 1 wt. % tween 80 
in distilled water has been produced. The mixture was stirred for some hours at room 
temperature, and then it was centrifuged and filtered. The filtered solution had a 
concentration of approximately 0.302 mg/ml after all experiments and all attempts.  30 ml 
of this solution (9.06 mg ART) was added to a gelatin solution, and the mixture was stirred 
for some hours. The spray drying of this mixture was done by mini spray dryer B-290 (Fig. 
58).  




Figure 58 spray-dryer B-290 
The adjusted parameters for the spray-drying of the solutions can be observed below in 
Table 8.  
Table 8 Adjusted instrumental parameters  
Inlet temperature (o C) 115 
Outlet temperature (o C) 75 
Aspirator (%) 100 
Pump (%)  10 
Gas flow (mm) 50 






Figure 59 Appearance of ART loaded gelatin microparticles  
 
4.10 In vivo controlled release of ART 
Mice were injected intraperitoneally with Plasmodium berghey ANKA. Inserts containing 
ART or blank inserts were introduced subcutaneously on different days post or before 
infection, as indicated. N represents a number of mice in the group, and D means dead. 
Death of mice with parasitemia below ~20% parasitemia accompanied by a typical 
disease is considered as the death of cerebral malaria (CM). All control mice died of CM. 
Each line represents a single mouse. All these experiments have been performed in the 
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4.11 Set-up for infusion experiments 
An infusion pump from B. Braun Melsungen was used together with a standard infusion 
system, as shown in Fig. 60. The drip chamber was opened, equipped with the ART-
loaded NFN, and closed again before the infusion experiment. 
 











































Cerebral malaria (CM) is a significant reason for malarial death, and its treatment is 
complicated because of the role of the parasite and the baneful immunopathological 
response. In the face of the etiology of CM, both anti-plasmodial and anti-inflammatory 
treatments are essential, in addition to adjunctive therapy.  
Currently, artemisinin derivatives are administrated as a first-line anti-malarial treatment. 
Artemisone (ART), being antiplasmodial and anti-inflammatory, was selected for the 
current studies. It is a lately produced artemisinin derivative with longer in vivo half-life 
relative to other derivatives and has a superior antiplasmodial activity. However, in mice 
models, repeated injections, twice a day for at least three days, are necessary for a 
significant anti-plasmodial effect. Artemisinin derivatives are poisonous at high 
concentrations that cannot be accurately controlled by the usual route of injections. Oral 
treatment may reduce toxicity. However, due to the very low absorption, much higher 
doses have to be used (limiting the use of the drugs for economic reasons). Although 
ART has improved pharmacokinetics compared to other artemisinins, low patient 
compliance may limit its use. As an alternative approach, we fabricated macromolecular 
carriers and incorporated the drug into such effective carriers, to enable the controlled 
release.  
In this work, different classifications of materials based on electrospun nanofibers, 
polymeric films, 3D structures, and particles could be successfully applied to carry the 
ART. Drug molecules could be efficiently immobilized in these materials, and the drug 
release from these carriers could be adequately studied. Effectively, the kinetics of the 
ART release from macromolecular carriers could be adjusted by modification of the 
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carrier. Polymeric structures that contained ART were inserted subcutaneously and 
released the drug during at least a week in non-toxic quantities that were sufficient to 
prevent or delay CM in a mouse model, even when applied at a very late stage of the 
disease. We demonstrate as a proof-of-concept this controlled-sustained release system 
for safe and effective treatment of malaria, underlining the benefits of treatment of CM 
where a conventional mode of treatment is complicated. Similar methods could be applied 
for other parasites that are sensitive to artemisinins.  
Until now, implantation is almost the unique suggested administration route for the 
delivery of drug-loaded scaffolds. Although implantation is seen as an efficient 
administration route, practical in vivo application possesses different complications that 
do not satisfy the need for programmable and straightforward drug administration. Our 
introduced concept presented in this work and its setup in frame of an infusion system is 
rather simple and could be manufactured even under sterile conditions by the placement 
of the ART-loaded polymeric carriers in the drip chamber of an infusion set. Overall, we 
could decouple the programmed release of drugs from the influence of the physiological 
environment and provided a precise and reproducible drug release with different release 
profiles for a drug with problems of low bioavailability, low solubility, and instability in an 
aqueous medium.  
Each type of the carriers offers different horizons for application. For example, in our 
studies, we could also successfully apply the ultra-light polymeric sponges as another 
classification of the macromolecular carriers for the delivery of ART. Polymeric fibrous 
sponges have been successfully used as a carrier system for the programmed release of 
the antimalarial drug ART. The extremely high pore volume of the sponges enables a 
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very high loading capacity of ART. In contrast and oppositely, the polymeric films as other 
classification of the carrier cannot offer such porosity characteristics but the rate of the 
drug release can be efficiently retarded. Furthermore, microparticles as another kind of 
carries could be investigated for delivery of ART. ART loaded gelatin microparticles could 
be successfully produced by spray-drying technique, and an accelerated rate of drug 
release could be achieved. 
Concretely in this Ph.D. work, a wide range of drug release behaviors not only in form of 
retarded release kinetics but also in increased (or even burst) form of release kinetics 
could be explicitly investigated and followed. The controlling handles responsible for a 
particular release profile are precisely under control (or better called managable) through 
the smart design and controlling of the macromolecular carries for delivery of the drug 
molecules.  
The ART-loaded polymeric structures provide an optimal platform for precise 
programmed drug release, which could also be applied in the future particularly for other 
hydrophobic drugs. For programmable release profiles, the smart design of the carries 
and furthermore optimization (such as coating) are essential and versatile enough as they 
provide excellent control of preparation, handling, and mass transfer. This work presents 
not only fundamental studies based on using the macromolecular carriers for the 
treatment of Malaria but also tries to offer a new paradigm for the programmed drug 
release from macromolecular structures. 
 

























Zerebrale Malaria (CM) ist ein wesentlicher Grund für den Malaria-Todesfälle, und ihre 
Behandlung ist aufgrund der Rolle des Parasiten und der verbannten 
immunopathologischen Reaktion kompliziert. Angesichts der Ätiologie von CM sind 
neben der Zusatztherapie sowohl anti-plasmodiale als auch entzündungshemmende 
Behandlungen unerlässlich. 
Derzeit werden Artemisininderivate als Erstbehandlung gegen Malaria verabreicht. 
Artemison (ART), das antiplasmodial und entzündungshemmend ist, wurde für die 
aktuellen Studien ausgewählt. Es ist ein kürzlich hergestelltes Artemisinin-Derivat mit 
einer längeren in vivo-Halbwertszeit im Vergleich zu anderen Derivaten und weist eine 
überlegene antiplasmodiale Aktivität auf. In Mäusemodellen sind jedoch wiederholte 
Injektionen zweimal täglich für mindestens drei Tage erforderlich, um eine signifikante 
antiplasmodiale Wirkung zu erzielen. Artemisininderivate sind in hohen Konzentrationen 
giftig, die auf dem üblichen Injektionsweg nicht genau kontrolliert werden können. Die 
orale Administration kann die Toxizität verringern. Aufgrund der sehr geringen Absorption 
müssen jedoch viel höhere Dosen verwendet werden, was die Verwendung der 
Arzneimittel aus wirtschaftlichen Gründen einschränkt. Obwohl ART die Pharmakokinetik 
im Vergleich zu anderen Artemisininen verbessert hat, kann eine geringe Compliance 
des Patienten die Verwendung einschränken. 
Als alternativen Ansatz stellten wir makromolekulare Träger her und bauten das 
Arzneimittel in solche wirksamen Träger ein, um die kontrollierte Freisetzung zu 
ermöglichen. 
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In dieser Arbeit konnten verschiedene Klassifikationen von Materialien auf der Basis von 
elektrogesponnenen Nanofasern, Polymerfilmen, 3D-Strukturen und Partikeln erfolgreich 
angewendet werden, um die ART zu tragen. Arzneimittelmoleküle können in diesen 
Materialien effizient immobilisiert werden, und die Arzneimittelfreisetzung aus diesen 
Trägern kann dann angemessen untersucht werden. Effektiv konnte die Kinetik der ART-
Freisetzung von makromolekularen Trägern durch Modifikation des Trägers eingestellt 
werden.  
Polymerstrukturen, die ART enthielten, wurden subkutan inseriert und setzten das 
Arzneimittel während mindestens einer Woche in nichttoxischen Mengen frei, die 
ausreichten, um CM in einem Mausmodell zu verhindern oder zu verzögern, selbst wenn 
es in einem sehr späten Stadium der Krankheit angewendet wurde. Als Proof-of-Concept 
demonstrieren wir dieses System mit kontrollierter verzögerter Freisetzung zur sicheren 
und wirksamen Behandlung von Malaria und unterstreichen die Vorteile der Behandlung 
von CM, wenn eine herkömmliche Behandlungsmethode kompliziert ist. Ähnliche 
Methoden könnten für andere Parasiten angewendet werden, die gegenüber 
Artemisininen empfindlich sind. 
Bis jetzt ist die Implantation fast der einzigartige empfohlene Verabreichungsweg für die 
Lieferung von arzneimittelbeladenen Gerüsten. Obwohl die Implantation als effizienter 
Verabreichungsweg angesehen wird, weist die praktische In-vivo-Anwendung 
verschiedene Komplikationen auf, die die Notwendigkeit einer programmierbaren und 
unkomplizierten Arzneimittelverabreichung nicht befriedigen. Unser in dieser Arbeit 
vorgestelltes Konzept und sein Aufbau im Rahmen eines Infusionssystems ist recht 
einfach und könnte auch unter sterilen Bedingungen hergestellt werden, indem die ART-
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beladenen Polymerträger in die Tropfkammer eines Infusionssets eingebracht werden. 
Insgesamt konnten wir die programmierte Freisetzung von Arzneimitteln vom Einfluss der 
physiologischen Umgebung entkoppeln und eine präzise und reproduzierbare 
Arzneimittelfreisetzung mit unterschiedlichen Freisetzungsprofilen für ein Arzneimittel mit 
Problemen von geringer Bioverfügbarkeit, geringer Löslichkeit und Instabilität in einem 
wässrigen Medium bereitstellen. 
Jeder Trägertyp bietet unterschiedliche Anwendungshorizonte. Zum Beispiel konnten wir 
in unseren Studien auch die ultraleichten Polymerschwämme erfolgreich als eine weitere 
Klassifizierung der makromolekularen Träger für die Abgabe von ART anwenden. 
Polymere faserige Schwämme wurden erfolgreich als Trägersystem für die 
programmierte Freisetzung des Malariamedikaments ART verwendet. Das extrem hohe 
Porenvolumen der Schwämme ermöglicht eine sehr hohe Belastbarkeit von ART. Im 
Gegensatz dazu und im Gegensatz dazu können die Polymerfilme als andere 
Klassifizierung des Trägers solche Porositätseigenschaften nicht bieten, aber die 
Geschwindigkeit der Arzneimittelfreisetzung kann effizient verzögert werden. Darüber 
hinaus könnten Mikropartikel als eine andere Art von Trägern für die Abgabe von ART 
untersucht werden. Mit ART beladene Gelatine-Mikropartikel konnten erfolgreich durch 
Sprühtrocknungstechnik hergestellt werden, und eine beschleunigte Geschwindigkeit der 
Arzneimittelfreisetzung konnte erreicht werden. 
Konkret in dieser Ph.D. Dissertation konnte ein breites Spektrum von 
Wirkstofffreisetzungsverhalten nicht nur in Form einer Kinetik der verzögerten 
Freisetzung, sondern auch in Form einer erhöhten (oder sogar platzenden) Form der 
Freisetzungskinetik explizit untersucht und verfolgt werden. Die Kontrollgriffe, die für ein 
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bestimmtes Freisetzungsprofil verantwortlich sind, werden durch das intelligente Design 
und die Kontrolle der makromolekularen Träger für die Abgabe der Arzneimittelmoleküle 
genau kontrolliert (oder besser als handhabbar bezeichnet). 
Die ART-beladenen Polymerstrukturen bieten eine optimale Plattform für eine präzise 
programmierte Arzneimittelfreisetzung, die auch in Zukunft insbesondere für andere 
hydrophobe Arzneimittel angewendet werden könnte. Für programmierbare 
Freigabeprofile sind das intelligente Design der Träger und darüber hinaus die 
Optimierung (z. B. Beschichtung) wesentlich und vielseitig genug, da sie eine 
hervorragende Kontrolle über Vorbereitung, Handhabung und Stoffaustausch bieten. 
Diese Arbeit präsentiert nicht nur grundlegende Studien, die auf der Verwendung der 
makromolekularen Träger zur Behandlung von Malaria basieren, sondern versucht auch, 
ein neues Paradigma für die programmierte Arzneimittelfreisetzung aus 
makromolekularen Strukturen anzubieten. 
  
































The introduction of nanotechnology has changed all scientific fields, including medical, 
pharmaceutical, and drug delivery systems radically. Nanotechnology has provided an 
excellent device to pharmaceutical scientists which is supportive in developing novel 
formulations of existing problematic drugs. The majority of the drugs administrated for 
treatment of dreaded diseases such as cancer, Malaria, and Leishmaniasis have poor 
selectivity and severe toxicity towards normal body cells. The toxicity of such drugs can 
be fundamentally decreased by incorporation inside nano- and microsized carrier 
systems. 
The presented studies in this thesis set a milestone to realize the strength and weakness 
points of different types of polymeric carriers for the delivery of a hydrophobic drug. 
Nowadays, there are many classes of the drug with the same characteristics as 
Artemisone. 
 
There are some interesting scientific aspects which can be observed as potential future 
works: 
 
• Application of dual or triple-drug release system by incorporation of other drug 
molecules such as antibiotics or anti-inflammatory agents in polymeric carriers: 
The incorporated drug molecules can consist of different natures in case of 
hydrophilicity or hydrophobicity. 
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•  Smart drug delivery system by incorporation of drugs in thermoresponsive 
particles and incorporation of particles in polymeric carriers. The system can be 
worked smartly on time in case of requirements like urgent, vital situations such as 
high grades of fever. 
 
• Drug-loaded 3D-structures offer many advantages as the polymeric carriers 
because of their high loading capacities. Furthermore, the shapes and forms of 
3D-structures play a vital role in controlling the kinetics of the drug release. In this 
field, complementary studies are needed. 
 
• Finally, as presented in this work, the introduced infusion system equipped with 
nanofibrous structures can be a useful device for the administration of drug-loaded 
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